Biostax Corp.
BTAX
Other OTC0.00
USD
- -
- -
CIK
0001559356
ISIN
US45252A3059
CUSIP
45252A305
Return %
Stock
S&P500
1Y
-50.00
18.99
3Y
-99.99
64.75
5Y
-100.00
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Noreen Griffin
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2431 Aloma Ave. Winter Park FL United States of America 32804
- IPO Date
- Aug 20, 2010
- CIK
- 0001559356
- Website
- biostaxcorp.com
- Similar Companies
- Business
- Biostax Corp. (BTAX) operates as a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing therapies targeting immune modulation, chronic inflammation, autoimmunity, HIV management, and related conditions; its core pipeline includes Lodonal, an approved once-daily immune system regulator for HIV/AIDS management in Nigeria demonstrating 44% CD4 count increases in trials versus 11% for standard care; JKB-122, a licensed long-acting toll-like receptor 4 (TLR4) antagonist for autoimmune hepatitis (AIH), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH) with FDA acceptance of three investigational new drug (IND) applications including Phase 2 trials and a new IND filing as HIV adjunct therapy; Low Dose Naltrexone (LDN) compounded formulations for cancer, pain, autoimmune disorders, and anti-aging; BiostaxRx, a wholly owned telehealth and inflammaging subsidiary offering compounded LDN, botanicals, nutraceuticals, bone health supplements, CBD products, neuroinflammation treatments, and blockchain-secured electronic health records (EHR) and prescription platforms; a smart contract MedTech program for secure patient data management; and a late-stage chronic kidney disease (CKD) treatment under non-binding letter of intent for hyperphosphatemia in end-stage renal disease (ESRD). The company maintains a hub-and-spoke model deploying products through subsidiaries, partnerships, and international programs in emerging markets including Africa and Asia, with a global telehealth platform and manufacturing of approved therapeutics and nutraceuticals. Founded in 1993 and headquartered at 2431 Aloma Avenue, Suite 124, Winter Park, Florida, Biostax Corp. underwent a name change from Immune Therapeutics, Inc. in October 2023 with FINRA approval of the BTAX ticker, signaling entry into substance abuse and HIV markets; recently announced a collaboration with Immgenuity, Inc. for HIV remission, a settlement and amended license with Statera Biopharma for clearer JKB-122 pathways, a growth funding round for affordable healthcare, voluntary delisting from OTC Pink in October 2024 to focus on JKB-122 amid 76.4% shareholder approval, and management changes to advance its repositioning strategy.
Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment